Value in Health: Defining a Core Data Set for the Economic Evaluation of Precision Oncology

August 9th, 2022|Categories: Featured, Industry News|Tags: , , , , |

Despite the growing abundance of multiomic data in precision oncology, the lack of standardization and interoperability impedes economic evaluation. In the latest issue of Value in Health, Samantha Pollard, PhD et al. found significant variability in published data resources. Through their work, they identified a core set of 68 data elements that they believe would support accurate and efficient economic evaluations.

Whitepaper – Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelinesv

August 8th, 2022|Categories: Featured, Industry News|Tags: , , , |

Despite a growing understanding of cancer biology, only 10% of cancer treatments approved by the FDA have an overall survival benefit for patients. A newly available white paper lays out the current precision medicine landscape and how the shift towards adaptive trial designs could accelerate market access and improve patient outcomes

Go to Top